(Q35914401)

11 August 2017

1 reference

title

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem (English)

1 reference

11 August 2017

1 reference

3

George L Drusano

1 reference

11 August 2017

4

David P Nicolau

1 reference

11 August 2017

Holly M Mattoes

1

1 reference

PubMed ID

15476901

11 August 2017

Joseph L Kuti

series ordinal

2

1 reference

11 August 2017

1 August 2004

1 reference

11 August 2017

Clinical Therapeutics

1 reference

11 August 2017

26

1 reference

11 August 2017

8

1 reference

11 August 2017

1187-1198

1 reference

Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility.

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Comparative pharmacokinetics of the carbapenems: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Meropenem clinical pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Prevention of resistance: a goal for dose selection for antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Application of fluoroquinolone pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

The pharmacodynamics of beta-lactams

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Postantibiotic effect of imipenem on Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacokinetics of meropenem in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Stability of meropenem in intravenous solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Stability of meropenem in a portable infusion device in a cold pouch

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Continuous infusion versus intermittent administration of meropenem in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980001-8

7 January 2021

10.1016/S0149-2918(04)80001-8

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15476901